Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age.

Abstract:

BACKGROUND:The underlying biological mechanisms through which epidemiologically defined breast cancer risk factors contribute to disease risk remain poorly understood. Identification of the molecular changes associated with cancer risk factors in normal tissues may aid in determining the earliest events of carcinogenesis and informing cancer prevention strategies. METHODS:Here we investigated the impact cancer risk factors have on the normal breast epigenome by analyzing DNA methylation genome-wide (Infinium 450 K array) in cancer-free women from the Susan G. Komen Tissue Bank (n = 100). We tested the relation of established breast cancer risk factors, age, body mass index, parity, and family history of disease, with DNA methylation adjusting for potential variation in cell-type proportions. RESULTS:We identified 787 cytosine-guanine dinucleotide (CpG) sites that demonstrated significant associations (Q value <0.01) with subject age. Notably, DNA methylation was not strongly associated with the other evaluated breast cancer risk factors. Age-related DNA methylation changes are primarily increases in methylation enriched at breast epithelial cell enhancer regions (P = 7.1E-20), and binding sites of chromatin remodelers (MYC and CTCF). We validated the age-related associations in two independent populations, using normal breast tissue samples (n = 18) and samples of normal tissue adjacent to tumor tissue (n = 97). The genomic regions classified as age-related were more likely to be regions altered in both pre-invasive (n = 40, P = 3.0E-03) and invasive breast tumors (n = 731, P = 1.1E-13). CONCLUSIONS:DNA methylation changes with age occur at regulatory regions, and are further exacerbated in cancer, suggesting that age influences breast cancer risk in part through its contribution to epigenetic dysregulation in normal breast tissue.

journal_name

Breast Cancer Res

authors

Johnson KC,Houseman EA,King JE,Christensen BC

doi

10.1186/s13058-017-0873-y

subject

Has Abstract

pub_date

2017-07-10 00:00:00

pages

81

issue

1

eissn

1465-5411

issn

1465-542X

pii

10.1186/s13058-017-0873-y

journal_volume

19

pub_type

杂志文章
  • Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

    abstract:BACKGROUND:Several anthropometric measures have been found to be associated with the risk of breast cancer. Current weight, body mass index, and adult weight gain appear to be predictors of postmenopausal breast cancer. These factors have been associated with a reduced risk of premenopausal breast cancer. We asked whet...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1293

    authors: Kotsopoulos J,Olopado OI,Ghadirian P,Lubinski J,Lynch HT,Isaacs C,Weber B,Kim-Sing C,Ainsworth P,Foulkes WD,Eisen A,Sun P,Narod SA

    更新日期:2005-01-01 00:00:00

  • Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

    abstract:INTRODUCTION:The HER (human EGFR related) family of receptor tyrosine kinases (HER1/EGFR (epidermal growth factor receptor)/c-erbB1, HER2/c-erbB2, HER3/c-erbB3 and HER4/c-erbB4) shares a high degree of structural and functional homology. It constitutes a complex network, coupling various extracellular ligands to intrac...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1843

    authors: Sassen A,Rochon J,Wild P,Hartmann A,Hofstaedter F,Schwarz S,Brockhoff G

    更新日期:2008-01-01 00:00:00

  • CD24(+) cells fuel rapid tumor growth and display high metastatic capacity.

    abstract:INTRODUCTION:Breast tumors are comprised of distinct cancer cell populations which differ in their tumorigenic and metastatic capacity. Characterization of cell surface markers enables investigators to distinguish between cancer stem cells and their counterparts. CD24 is a well-known cell surface marker for mammary epi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0589-9

    authors: Rostoker R,Abelson S,Genkin I,Ben-Shmuel S,Sachidanandam R,Scheinman EJ,Bitton-Worms K,Orr ZS,Caspi A,Tzukerman M,LeRoith D

    更新日期:2015-06-04 00:00:00

  • Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

    abstract::The key to optimising our approach in early breast cancer is to individualise care. Each patient has a tumour with innate features that dictate their chance of relapse and their responsiveness to treatment. Often patients with similar clinical and pathological tumours will have markedly different outcomes and response...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2238

    authors: Oakman C,Bessi S,Zafarana E,Galardi F,Biganzoli L,Di Leo A

    更新日期:2009-01-01 00:00:00

  • Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

    abstract:BACKGROUND:The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer pat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1127-y

    authors: Kennedy SP,Han JZR,Portman N,Nobis M,Hastings JF,Murphy KJ,Latham SL,Cadell AL,Miladinovic D,Marriott GR,O'Donnell YEI,Shearer RF,Williams JT,Munoz AG,Cox TR,Watkins DN,Saunders DN,Timpson P,Lim E,Kolch W,Croucher

    更新日期:2019-03-21 00:00:00

  • Involution of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3.

    abstract:INTRODUCTION:Involution of the mammary gland is a complex process of controlled apoptosis and tissue remodelling. The aim of the project was to identify genes that are specifically involved in this process. METHODS:We used Affymetrix oligonucleotide microarrays to perform a detailed transcript analysis on the mechanis...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr753

    authors: Stein T,Morris JS,Davies CR,Weber-Hall SJ,Duffy MA,Heath VJ,Bell AK,Ferrier RK,Sandilands GP,Gusterson BA

    更新日期:2004-01-01 00:00:00

  • Pre-analytic variables and phospho-specific antibodies: the Achilles heel of immunohistochemistry.

    abstract::Immunohistochemistry is the most common method for companion diagnostic testing in breast cancer. The readings for estrogen receptor, progesterone receptor, and Her2 directly affect prescription of critical therapies. However, immunohistochemistry is highly sensitive to innumerable pre-analytic variables that result i...

    journal_title:Breast cancer research : BCR

    pub_type: 社论

    doi:10.1186/bcr2782

    authors: Siddiqui S,Rimm DL

    更新日期:2010-01-01 00:00:00

  • Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.

    abstract::ErbB (also termed HER) receptors are expressed in various tissues of epithelial, mesenchymal and neuronal origin, in which they are involved in the control of diverse biological processes such as proliferation, differentiation, migration and apoptosis. Furthermore, their deregulated expression has been implicated in m...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr327

    authors: Olayioye MA

    更新日期:2001-01-01 00:00:00

  • Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms.

    abstract::Accumulating evidence suggests that many cancers, including BRCA1- and BRCA2-associated breast cancers, are deficient in DNA repair processes. Both hereditary and sporadic breast cancers have been found to have significant downregulation of repair factors. This has provided opportunities to exploit DNA repair deficien...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2566

    authors: Rowe BP,Glazer PM

    更新日期:2010-01-01 00:00:00

  • Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

    abstract::Gene therapy is a therapeutic approach that is designed to correct specific molecular defects that contribute to the cause or progression of cancer. Genes that are mutated or deleted in cancers include the cancer susceptibility genes p53 and BRCA1. Because mutational inactivation of gene function is specific to tumor ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr26

    authors: Obermiller PS,Tait DL,Holt JT

    更新日期:2000-01-01 00:00:00

  • Does diet affect breast cancer risk?

    abstract::The role of specific dietary factors in breast cancer causation is not completely resolved. Results from prospective studies do not support the concept that fat intake in middle life has a major relation to breast cancer risk. However, weight gain in middle life contributes substantially to breast cancer risk. Alcohol...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr909

    authors: Holmes MD,Willett WC

    更新日期:2004-01-01 00:00:00

  • An investigation of soy intake and mammographic characteristics in Hawaii.

    abstract::This cross-sectional investigation in Hawaii explored the relation between soy foods and mammographic characteristics using two food frequency questionnaires and a computer-assisted density assessment method. Japanese and Chinese women reported significantly greater soy food intake than Caucasian women. Whereas soy in...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr285

    authors: Maskarinec G,Meng L

    更新日期:2001-01-01 00:00:00

  • Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer.

    abstract:BACKGROUND:Chemotherapy is the standard treatment for breast cancer; however, the response to chemotherapy is disappointingly low. Here, we investigated the alternative therapeutic efficacy of novel combination treatment with necroptosis-inducing small molecules to overcome chemotherapeutic resistance in tyrosine amino...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01367-7

    authors: Lee KM,Lee H,Han D,Moon WK,Kim K,Oh HJ,Choi J,Hwang EH,Kang SE,Im SA,Lee KH,Ryu HS

    更新日期:2020-11-25 00:00:00

  • The role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processes.

    abstract::Turnover of several regulatory proteins results from targeted destruction via ubiquitination and subsequent degradation through the proteosome. The timely and irreversible degradation of critical regulators is essential for normal cellular function. The precise biochemical mechanisms that are involved in protein turno...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr542

    authors: Rossi S,Loda M

    更新日期:2003-01-01 00:00:00

  • Circulating DNA as biomarker in breast cancer.

    abstract::As the release of tumor-associated DNA into blood circulation is a common event in patients with cancer, screening of plasma or serum DNA may provide information on genetic and epigenetic profiles associated with breast cancer development, progression, and response to therapy. Quantitative testing of circulating DNA c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0645-5

    authors: Schwarzenbach H,Pantel K

    更新日期:2015-10-09 00:00:00

  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

    abstract:INTRODUCTION:Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondria...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0567-2

    authors: Blein S,Bardel C,Danjean V,McGuffog L,Healey S,Barrowdale D,Lee A,Dennis J,Kuchenbaecker KB,Soucy P,Terry MB,Chung WK,Goldgar DE,Buys SS,Breast Cancer Family Registry.,Janavicius R,Tihomirova L,Tung N,Dorfling CM,va

    更新日期:2015-04-25 00:00:00

  • Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.

    abstract:BACKGROUND:The BRCA1 c.3331_3334delCAAG founder mutation has been reported in hereditary breast and ovarian cancer families from multiple Hispanic groups. We aimed to evaluate BRCA1 c.3331_3334delCAAG haplotype diversity in cases of European, African, and Latin American ancestry. METHODS:BC mutation carrier cases from...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01341-3

    authors: Tuazon AMA,Lott P,Bohórquez M,Benavides J,Ramirez C,Criollo A,Estrada-Florez A,Mateus G,Velez A,Carmona J,Olaya J,Garcia E,Polanco-Echeverry G,Stultz J,Alvarez C,Tapia T,Ashton-Prolla P,Brazilian Familial Cancer Network

    更新日期:2020-10-21 00:00:00

  • High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer.

    abstract::It is generally accepted that early detection of breast cancer has great impact on patient survival, emphasizing the importance of early diagnosis. In a widely recognized model of breast cancer development, tumor cells progress through chronological and well defined stages. However, the molecular basis of disease prog...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1528

    authors: Rennstam K,Hedenfalk I

    更新日期:2006-01-01 00:00:00

  • Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer.

    abstract:INTRODUCTION:The amplification event occurring at chromosome locus 11q13, reported in several different cancers, includes a number of potential oncogenes. We have previously reported amplification of one such oncogene, namely CCND1, to be correlated with an adverse effect of tamoxifen in premenopausal breast cancer pat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2150

    authors: Lundgren K,Holm K,Nordenskjöld B,Borg A,Landberg G

    更新日期:2008-01-01 00:00:00

  • Targeted therapy against Bcl-2-related proteins in breast cancer cells.

    abstract:INTRODUCTION:Bcl-2 and Bcl-xL confer resistance to apoptosis, thereby reducing the effectiveness of chemotherapy. We examined the relationship between the expression of Bcl-2 and Bcl-xL and chemosensitivity of breast cancer cells, with the aim of developing specific targeted therapy. METHODS:Four human breast cancer c...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1323

    authors: Emi M,Kim R,Tanabe K,Uchida Y,Toge T

    更新日期:2005-01-01 00:00:00

  • Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan.

    abstract:INTRODUCTION:The neuron-glial antigen 2 (NG2) proteoglycan promotes pericyte recruitment and mediates pericyte interaction with endothelial cells. In the absence of NG2, blood vessel development is negatively impacted in several pathological models. Our goal in this study was to determine the effect of NG2 ablation on ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3174

    authors: Gibby K,You WK,Kadoya K,Helgadottir H,Young LJ,Ellies LG,Chang Y,Cardiff RD,Stallcup WB

    更新日期:2012-04-24 00:00:00

  • Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions.

    abstract::Adjuvant hormonal therapy for postmenopausal women with early stage breast cancer has become far more complex over the past several years. This commentary reviews the current status of the five major trials evaluating the use of the aromatase inhibitors in the adjuvant setting. The data currently available suggest tha...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1347

    authors: Ligibel JA,Winer EP

    更新日期:2005-01-01 00:00:00

  • BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.

    abstract:BACKGROUND:In breast cancer, BRCA promoter hypermethylation and BRCA germline mutations are said to occur together rarely, but this property has not yet been translated into a clinical test. Our aim in this study was to investigate the diagnostic value of BRCA1/2 methylation in distinguishing breast carcinomas of BRCA1...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0856-z

    authors: Vos S,Moelans CB,van Diest PJ

    更新日期:2017-05-31 00:00:00

  • Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

    abstract::Genome-wide expression microarray studies have revealed that the biological and clinical heterogeneity of breast cancer can be partly explained by information embedded within a complex but ordered transcriptional architecture. Comprising this architecture are gene expression networks, or signatures, reflecting biochem...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1662

    authors: Miller LD,Liu ET

    更新日期:2007-01-01 00:00:00

  • Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case-control study.

    abstract:INTRODUCTION:The ataxia telangiectasia mutated (ATM) gene is a tumor suppressor gene with functions in cell cycle arrest, apoptosis, and repair of DNA double-strand breaks. Based on family studies, women heterozygous for mutations in the ATM gene are reported to have a fourfold to fivefold increased risk of breast canc...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr809

    authors: Tamimi RM,Hankinson SE,Spiegelman D,Kraft P,Colditz GA,Hunter DJ

    更新日期:2004-01-01 00:00:00

  • Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.

    abstract:INTRODUCTION:Mammary-specific overexpression of Six1 in mice induces tumors that resemble human breast cancer, some having undergone epithelial to mesenchymal transition (EMT) and exhibiting stem/progenitor cell features. Six1 overexpression in human breast cancer cells promotes EMT and metastatic dissemination. We hyp...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3219

    authors: Iwanaga R,Wang CA,Micalizzi DS,Harrell JC,Jedlicka P,Sartorius CA,Kabos P,Farabaugh SM,Bradford AP,Ford HL

    更新日期:2012-07-05 00:00:00

  • Frequency and spectrum of PIK3CA somatic mutations in breast cancer.

    abstract:PURPOSE:The therascreen PIK3CA mutation assay and the alpha-specific PI3K inhibitor alpelisib are FDA-approved for identifying and treating patients with advanced PIK3CA-mutated (PIK3CAmut) breast cancer (BC). However, it is currently unknown to what extend this assay detects most PIK3CA mutations in BC. This informati...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01284-9

    authors: Martínez-Sáez O,Chic N,Pascual T,Adamo B,Vidal M,González-Farré B,Sanfeliu E,Schettini F,Conte B,Brasó-Maristany F,Rodríguez A,Martínez D,Galván P,Rodríguez AB,Martinez A,Muñoz M,Prat A

    更新日期:2020-05-13 00:00:00

  • Nighttime eating and breast cancer among Chinese women in Hong Kong.

    abstract:BACKGROUND:A novel line of research suggests that eating at nighttime may have several metabolic consequences that are highly relevant to breast cancer. We investigated the association between nighttime eating habits after 10 p.m. and breast cancer in Hong Kong women. METHODS:A hospital-based case-control study was co...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0821-x

    authors: Li M,Tse LA,Chan WC,Kwok CH,Leung SL,Wu C,Yu WC,Lee PM,Tsang KH,Law SH,Vermeulen R,Gu F,Caporaso NE,Yu IT,Wang F,Yang XR

    更新日期:2017-03-17 00:00:00

  • A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

    abstract:INTRODUCTION:There is an unmet clinical need for biomarkers to identify breast cancer patients at an increased risk of developing brain metastases. The objective is to identify gene signatures and biological pathways associated with human epidermal growth factor receptor 2-positive (HER2+) brain metastasis. METHODS:We...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3625

    authors: McMullin RP,Wittner BS,Yang C,Denton-Schneider BR,Hicks D,Singavarapu R,Moulis S,Lee J,Akbari MR,Narod SA,Aldape KD,Steeg PS,Ramaswamy S,Sgroi DC

    更新日期:2014-03-14 00:00:00

  • FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

    abstract:BACKGROUND:Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adh...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01298-3

    authors: Paul R,Luo M,Mo X,Lu J,Yeo SK,Guan JL

    更新日期:2020-06-03 00:00:00